Risk of Brain Metastases in T1-3N0 NSCLC: a Population-based Analysis

Overview

Journal Lung Cancer Manag

Date 2020 Apr 8

PMID 32256710

Citations 5

Authors

Michael T Milano

James E Bates

Justin Budnik

Haoming Qiu

Sara Hardy

Michael A Cummings

Megan A Baumgart

Ronald J Maggiore

Deborah A Mulford

Kenneth Y Usuki

Affiliations

Soon will be listed here.

Abstract

Aim: Several consensus guidelines recommend against routine brain imaging at diagnosis of T1-3N0 non-small cell lung cancer (NSCLC).

Methods: From the Surveillance, Epidemiology and End Results registry, patients with pathologically confirmed T1-3N0 NSCLC were identified. Risks of brain metastases at time of initial diagnosis were analyzed.

Results: Patients selected to not undergo primary NSCLC resection had approximately tenfold greater incidence of brain metastases versus those who did. Younger age, adenocarcinoma histology, higher tumor stage and higher histologic grade were all significantly (p < 0.0001) associated with greater likelihood of presenting with brain metastases.

Conclusion: Given the morbidity and mortality of brain metastases, routine brain screening after NSCLC diagnosis (particularly adenocarcinoma) may be justifiable, though more refined cost-benefit analyses are warranted.

Citing Articles

Tumor-to-Tumor Metastasis of Lung Cancer to Kidney Cancer: A Review of the Literature and Our Experience.

Baston C, Parosanu A, Mihai M, Moldoveanu O, Stanciu I, Nitipir C Diagnostics (Basel). 2024; 14(5).

PMID: 38473025 PMC: 10930794. DOI: 10.3390/diagnostics14050553.

Diagnostic Workup, Treatment Patterns, and Clinical Outcomes in Early-Stage IB-IIIA Non-Small-Cell Lung Cancer Patients in Denmark.

Uldbjerg E, Ringgaard L, Andersen K, Frederiksen L, Jovanovic A, Meldgaard P Cancers (Basel). 2023; 15(21).

PMID: 37958305 PMC: 10647574. DOI: 10.3390/cancers15215130.

Brain metastasis screening in the molecular age.

Tabor J, Onoichenco A, Narayan V, Wernicke A, DAmico R, Vojnic M Neurooncol Adv. 2023; 5(1):vdad080.

PMID: 37484759 PMC: 10358433. DOI: 10.1093/noajnl/vdad080.

Clinical features and molecular genetics associated with brain metastasis in suspected early-stage non-small cell lung cancer.

Kim K, Lee J, Lee J, Yong S, Kim E, Jung J Front Oncol. 2023; 13:1148475.

PMID: 37139160 PMC: 10150586. DOI: 10.3389/fonc.2023.1148475.

BSREM for Brain Metastasis Detection with 18F-FDG-PET/CT in Lung Cancer Patients.

Liberini V, Pizzuto D, Messerli M, Orita E, Grunig H, Maurer A J Digit Imaging. 2022; 35(3):581-593.

PMID: 35212859 PMC: 9156589. DOI: 10.1007/s10278-021-00570-y.

References

Brastianos P, Carter S, Santagata S, Cahill D, Taylor-Weiner A, Jones R . Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015; 5(11):1164-1177. PMC: 4916970. DOI: 10.1158/2159-8290.CD-15-0369. View

Postmus P, Kerr K, Oudkerk M, Senan S, Waller D, Vansteenkiste J . Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4):iv1-iv21. DOI: 10.1093/annonc/mdx222. View

Schouten L, Rutten J, Huveneers H, Twijnstra A . Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 2002; 94(10):2698-705. DOI: 10.1002/cncr.10541. View

An N, Jing W, Wang H, Li J, Liu Y, Yu J . Risk factors for brain metastases in patients with non-small-cell lung cancer. Cancer Med. 2018; 7(12):6357-6364. PMC: 6308070. DOI: 10.1002/cam4.1865. View

Hudson Z, Internullo E, Edey A, Laurence I, Bianchi D, Addeo A . Brain imaging before primary lung cancer resection: a controversial topic. Ecancermedicalscience. 2017; 11:749. PMC: 5493439. DOI: 10.3332/ecancer.2017.749. View

Patil T, Smith D, Bunn P, Aisner D, Le A, Hancock M . The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. J Thorac Oncol. 2018; 13(11):1717-1726. PMC: 6204290. DOI: 10.1016/j.jtho.2018.07.001. View

Iuchi T, Shingyoji M, Itakura M, Yokoi S, Moriya Y, Tamura H . Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations. Int J Clin Oncol. 2014; 20(4):674-9. DOI: 10.1007/s10147-014-0760-9. View

Goncalves P, Peterson S, Vigneau F, Shore R, Quarshie W, Islam K . Risk of brain metastases in patients with nonmetastatic lung cancer: Analysis of the Metropolitan Detroit Surveillance, Epidemiology, and End Results (SEER) data. Cancer. 2016; 122(12):1921-7. PMC: 4892979. DOI: 10.1002/cncr.30000. View

Kromer C, Xu J, Ostrom Q, Gittleman H, Kruchko C, Sawaya R . Estimating the annual frequency of synchronous brain metastasis in the United States 2010-2013: a population-based study. J Neurooncol. 2017; 134(1):55-64. DOI: 10.1007/s11060-017-2516-7. View

10.

Remon J, Besse B . Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment. Front Oncol. 2018; 8:88. PMC: 5904204. DOI: 10.3389/fonc.2018.00088. View

11.

Cagney D, Martin A, Catalano P, Redig A, Lin N, Lee E . Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017; 19(11):1511-1521. PMC: 5737512. DOI: 10.1093/neuonc/nox077. View

12.

Sperduto P, Yang T, Beal K, Pan H, Brown P, Bangdiwala A . Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA). JAMA Oncol. 2016; 3(6):827-831. PMC: 5824323. DOI: 10.1001/jamaoncol.2016.3834. View

13.

Griesinger F, Roeper J, Pottgen C, Willborn K, Eberhardt W . Brain metastases in ALK-positive NSCLC - time to adjust current treatment algorithms. Oncotarget. 2018; 9(80):35181-35194. PMC: 6205553. DOI: 10.18632/oncotarget.26073. View

14.

Peters S, Bexelius C, Munk V, Leighl N . The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. Cancer Treat Rev. 2016; 45:139-62. DOI: 10.1016/j.ctrv.2016.03.009. View

15.

Waqar S, Waqar S, Trinkaus K, Gadea C, Robinson C, Bradley J . Brain Metastases at Presentation in Patients With Non-Small Cell Lung Cancer. Am J Clin Oncol. 2015; 41(1):36-40. PMC: 4833709. DOI: 10.1097/COC.0000000000000230. View

16.

Lim E, Baldwin D, Beckles M, Duffy J, Entwisle J, Faivre-Finn C . Guidelines on the radical management of patients with lung cancer. Thorax. 2010; 65 Suppl 3:iii1-27. DOI: 10.1136/thx.2010.145938. View

17.

. Pretreatment evaluation of non-small-cell lung cancer. The American Thoracic Society and The European Respiratory Society. Am J Respir Crit Care Med. 1997; 156(1):320-32. DOI: 10.1164/ajrccm.156.1.ats156.1. View

18.

Waqar S, Samson P, Robinson C, Bradley J, Devarakonda S, Du L . Non-small-cell Lung Cancer With Brain Metastasis at Presentation. Clin Lung Cancer. 2018; 19(4):e373-e379. PMC: 6990432. DOI: 10.1016/j.cllc.2018.01.007. View

19.

Villano J, Durbin E, Normandeau C, Thakkar J, Moirangthem V, Davis F . Incidence of brain metastasis at initial presentation of lung cancer. Neuro Oncol. 2014; 17(1):122-8. PMC: 4483041. DOI: 10.1093/neuonc/nou099. View

20.

Rice S, Molitoris J, Vyfhuis M, Edelman M, Burrows W, Feliciano J . Lymph Node Size Predicts for Asymptomatic Brain Metastases in Patients With Non-small-cell Lung Cancer at Diagnosis. Clin Lung Cancer. 2018; 20(1):e107-e114. DOI: 10.1016/j.cllc.2018.09.014. View